Sulje

FI - FI


Please select a country and, if applicable, a language.

Artikkelien yleiskatsaus

Acute cough: for the first time, a clear recommendation for ambroxol as symptomatic treatment


According to the guidelines of the German Respiratory Society, an acute cold cough without clinical indications of pneumonia or other warning signs, is the domain of self-medication. The duration – up ...

Artikkeliin
Kirjoittaja: Tobias Mück, PhDEFSM: 2021;1:210002DOI: 10.52778/efsm.21.0002Päivämäärä: 16.08.2021

Ambroxol reduces cough frequency (in the daytime and at night) and thereby improves concentration …


The pharmacy-based study questioned customers who had used one of four different dosage forms of ambroxol for acute cough. The results illustrated the therapeutic benefits of ambroxol in self-medicati ...

Artikkeliin
Kirjoittaja: Tobias Mück, PhDEFSM: 2021;1:210003DOI: 10.52778/efsm.21.0003Päivämäärä: 16.08.2021

Pharmacokinetics of ibuprofen: comparison of the fixed combination of ibuprofen plus caffeine with …

Results of two single-dose studies (randomised, single centre, crossover, open-label)


Analgesics containing readily soluble ibuprofen (e.g. as the lysinate) were developed with the aim of ensuring a more rapid relief of pain than ibuprofen acid through faster absorption in the gastroin ...

Artikkeliin
Kirjoittaja: Thomas Weiser, PhDEFSM: 2021;1:210007DOI: 10.52778/efsm.21.0007Päivämäärä: 16.08.2021

Efficacy, safety and tolerability of the fixed combination of ibuprofen (400 mg) and caffeine (100 …

Results of a clinical study (randomised, placebo-controlled, double-blind)


Does combining ibuprofen with caffeine have advantages over ibuprofen alone in the treatment of acute pain? A randomised, placebo-controlled, double-blind study compared efficacy, safety and tolerabil ...

Artikkeliin
Kirjoittaja: Thomas Weiser, PhDEFSM: 2021;1:210008DOI: 10.52778/efsm.0008Päivämäärä: 16.08.2021

Abdominal pain, cramping and discomfort impair women's quality of life: an internet-based …


In this internet-based observational study, 96% of the women questioned reported that abdominal pain, cramping and discomfort sometimes interfered with their everyday activities; 44% even stated that ...

Artikkeliin
Kirjoittaja: Harald Weigmann, PhDEFSM: 2021;1:210009DOI: 10.52778/efsm.21.0009Päivämäärä: 16.08.2021

Guideline recommendations for the treatment of abdominal pain (in irritable bowel syndrome)


Abdominal pain is common and impairs quality of life. Many specialist societies across the world have formulated guidelines on the treatment of irritable bowel syndrome and all of them mention antispa ...

Artikkeliin
Kirjoittaja: Thomas Weiser, PhDEFSM: 2021;1:210010DOI: 10.52778/efsm.21.0010Päivämäärä: 16.08.2021

Healthy adults with severe stress and hypomagnesaemia benefit from a combination of magnesium and …


This randomised, single-blind, clinical study investigated the effects of magnesium supplementation compared with combined administration of magnesium and vitamin B6. Whilst there were no significant ...

Artikkeliin
Kirjoittaja: Marion Eberlin, PhDEFSM: 2021;1:210011DOI: 10.52778/efsm.21.0011Päivämäärä: 16.08.2021

Treatment of acute pain: comparison of the efficacy of ibuprofen lysinate and ibuprofen


Relief that is rapid and effective is wanted when treating pain. A double-blind, placebo-controlled study investigated the efficacy, safety and tolerability of ibuprofen lysinate, ibuprofen acid and p ...

Artikkeliin
Kirjoittaja: Thomas Weiser, PhDEFSM: 2021;1:210012DOI: 10.52778/efsm.21.0012Päivämäärä: 16.08.2021

Recent meta-analysis on the efficacy of peppermint oil in irritable bowel syndrome


The meta-analysis demonstrated that peppermint oil is an effective and safe medicinal agent for treating the symptoms of irritable bowel syndrome. In seven clinical studies, peppermint oil was clearly ...

Artikkeliin
Kirjoittaja: Harald Weigmann, PhDEFSM: 2021;1:210013DOI: 10.52778/efsm.21.0013Päivämäärä: 16.08.2021

Caffeine – stimulating and aromatic: but safe!


The European Food Safety Authority has undertaken a comprehensive risk assessment and concluded that life-long regular consumption of caffeine of up to 400 mg daily from the age of 18 by healthy adult ...

Artikkeliin
Kirjoittaja: Thomas Weiser, PhDEFSM: 2021;1:210014DOI: 10.52778/efsm.21.0014Päivämäärä: 16.08.2021